Bio-Rad Laboratories (BIO) investor relations material

Leadership and strategic priorities

• New leadership team aligned over the past 18–24 months, focusing on innovation, infrastructure, and commercial transformation.

• Emphasis on evaluating business elements, identifying growth opportunities, and improving pricing discipline.

• Operational improvements include manufacturing expansion in China and distribution network optimization.

• R&D portfolio reevaluated, resulting in impairments and renewed focus on digital PCR.

• Transitioning over 400,000 assays to new Stilla platforms to drive execution and growth.

R&D and M&A strategy

• Historical M&A focused on early-stage companies with mixed results; now prioritizing targets with on-market products and revenue.

• Stilla acquisition exemplifies new approach, contributing to 24% YoY instrument growth in ddPCR.

• M&A targets in the $100M–$500M range, with less emphasis on transformative deals.

• Focus on additive capabilities that leverage existing infrastructure for margin expansion.

• Portfolio pruning and potential divestitures are under ongoing evaluation.

Product and market initiatives

• Next-gen Bio-Plex platform launch on track, with focus on menu expansion and replacement cycle.

• Menu expansion expected to drive reagent rental and consumable pull-through, though specifics are still early.

• Digital PCR instrument growth driven by portfolio breadth, assay library, and technical publications.

• Consumables for digital PCR declined mid-single digits YoY, with lag in pull-through due to market softness.

• Process Chromatography business reset due to policy changes, aiming for high single-digit growth over time.